Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2015. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
- Issued Share Capital (as of July 31, 2015): 5,358,023,926 Ordinary Shares of 25p each.
- Treasury Shares: 491,515,950 Ordinary Shares.
- Total Voting Rights: 4,866,507,976.
Material Changes
The filing does not contain comparative financial data or discuss material changes versus prior periods. It provides a static snapshot of the share capital structure as of July 31, 2015.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or discussion of contingencies and unusual items. Its sole purpose is to inform shareholders of the denominator to be used for calculating notification thresholds under the Financial Conduct Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (4,866,507,976) against the company's latest annual report to ensure accurate calculation of ownership thresholds.
- Confirm the number of treasury shares held (491,515,950) to understand the difference between issued capital and voting capital.
- Note that this filing does not contain financial performance data; investors should refer to Form 20-F or quarterly earnings releases for financial metrics.